China Universal Asset Management Co., Ltd. Gracell Biotechnologies Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 May 21, 2024	BUY	$2.43 - $10.04 $20,424 - $84,386	8,405 New	8,405 $84,000
Q4 2023 Jan 23, 2024	BUY	$2.43 - $10.04 $16,176 - $66,836	6,657 Added 380.84%	8,405 $84,000
Q3 2023 May 21, 2024	BUY	$2.83 - $4.9 $2,419 - $4,189	855 Added 95.74%	1,748 $5,000
Q3 2023 Oct 30, 2023	BUY	$2.83 - $4.9 $2,419 - $4,189	855 Added 95.74%	1,748 $5,000
Q2 2023 May 21, 2024	SELL	$1.45 - $6.07 $14 - $60	-10 Reduced 1.11%	893 $3,000
Q2 2023 Jul 27, 2023	SELL	$1.45 - $6.07 $14 - $60	-10 Reduced 1.11%	893 $3,000
Q1 2023 May 21, 2024	BUY	$1.8 - $2.5 $405 - $562	225 Added 33.19%	903 $1,000
Q1 2023 Apr 27, 2023	BUY	$1.8 - $2.5 $405 - $562	225 Added 33.19%	903 $2,000
Q4 2022 May 21, 2024	BUY	$2.08 - $3.96 $1,410 - $2,684	678 New	678 $1,000
Q4 2022 Jan 31, 2023	BUY	$2.08 - $3.96 $112 - $213	54 Added 8.65%	678 $2,000
Q3 2022 Oct 21, 2022	BUY	$2.08 - $5.15 $1,297 - $3,213	624 New	624 $2,000

Others Institutions Holding GRCL

# of Institutions

Shares Held

75.1K

Call Options Held

Put Options Held

View Full List

About Gracell Biotechnologies Inc.

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

More about GRCL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account